ISOT-1xx

ISOT-1xx is a preclinical-stage drug discovery platform developed by IsoThrive, focused on identifying and developing therapeutic candidates for gastrointestinal (GI) diseases. The platform leverages IsoThrive's expertise in microbiome-modulating carbohydrates to target specific gut health pathways. While specific molecular targets for the ISOT-1xx series are not publicly disclosed, the program aims to address unmet needs in GI health through the modulation of the gut microbiome and its metabolic outputs. As a discovery-stage initiative, ISOT-1xx represents a series of potential drug candidates rather than a single defined molecule.